Skip to main content

Table 1 Studies on asthma

From: Health-related quality of life measurement in asthma and chronic obstructive pulmonary disease: review of the 2009-2014 literature

Drugs Baseline Final score Statistical significancea Clinical significance Reference
flut/form 500/20 μg 4.42 ± 0.89 5.34 ± 1.07 P = 0.036   Bodzenta-Lukaszyk et al. Resp Med 105 674-682 2011 [13]
flut + form 500 + 24 μg 4.57 ± 0.99 5.30 ± 1.00
flut/form250/10 μg Not reported Mean improvement of 0.8 in both treatment groups ns 55 % Bodzenta-Lukaszyk et a.l Journal of Asthma 49(10), 1060-1070, 2012 [14]
bud/form400/12 μg 57.6 % ns
flut/form combo 4.8 ± 1.1 5.5 ± 1.1 ns Not available Bodzenta-Lukaszyk et al. Current Medical Research and Opinion 29, 5 579-588, 2013 [15]
flut + form 4.9 ± 1.2 5.6 ± 1.0
Tio 5 μg add on 4.8 in all groups Change of 0.1 points for both active treatments compared with placebo ns Not available Kerstjens et al. Journal of Allergy Clin Immunol 128, 2 308-314, 2011 [16]
Tio 10 μg add on
Plac add on
Trial 1     Not achieved Kerstjens et al. New England Journal of Medicine 367:1198-1207, 2012 [17]
Tio 5 μg/die add on 4.6 ± 1.1 5.15 Ns
plac add on 4.6 ± 1.1 5.1 Ns (p < 0.05 al week 24
Trial 2   
Tio 5 μg/die add on 4.6 ± 1.0 5.1
plac add on 4.7 ± 1.1 4.93
Bud/formSMART 4.78 4.81 ns Not available – measurement of Satisfaction with Asthma Treatment Questionnaire Louis R et al. The International Journal of Clinical Practice 63, 10 1479-1488, 2009 [18]
Conventional best practice 4.78 4.82
Tio   5.58 P = 0.01 Not available Peters et al. New England Journal of Medicine 363 18 1715-1726, 2010 [19]
Double glucocorticoid 5.43 ± 1.05 5.48 P = 0.38
salm   5.71 P < 0.001
Flut fur/vil 200/25 μg Not available Baseline + 0.93 ± 0.065 ns Not available O’Byrne et al. Eur. Resp. Journal 43 773-782, 2014 [20]
Flut fur.200 μg   Baseline + 0.88 ± 0.071
Flut prop.500 μg   Baseline + 0.90 ± 0.068
Flut. fur/vil 100/25 μg 5.35 5.85 ns 46 % Woodcock et al. Chest 144(4), 1222-1229, 2013 [21]
flut. pro/salm 250/50 μg 5.37 5.79   38 %
salm 50 μg 5.175 Baseline + 0.280 ns Not available Bateman et al. J. Allergy Clin Immunol128, 315-322, 2011 [22]
tio 5 μg   Baseline + 0.131
plac   Baseline + 0.039   Not available
Adjustable bud/form AQLQ AQLQ AQLQ AQLQ O’Connor et al. Journal of Asthma 47 217-223, 2010 [10]
Fixed bud/form Not available Not available P < 0.04* 66.7 %
Adjustable bud/form    Nsb 63.0 %
     61.9 %
     No clinical difference between groups
  1. aBetween groups
  2. bFixed-dose regimen baseline vs end of treatment
  3. *Adjustable dosing vs fixed dose regimen
  4. p ≤ 0.002 vs fluticasone propionate/salmeterol